The role of sentinel lymph node biopsy for melanoma

Seminars in Oncology

Volumn 29, Issue 4, 2002, Pages 341-352

  Shen, Jeannie ^a   Wallace, Anne M ^a   Bouvet, Michael ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYE; RADIOISOTOPE;

ARTICLE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MELANOMA; MICROSCOPY; MORBIDITY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 0036340528     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34112     Document Type: Article

References (64)

1. Cancer statistics, 2001
2. The rate of malignant melanoma in the United States: Are we making an impact?
3. Multivariate analysis of the relationsip between survival and the microstage of primary melanoma by Clark level and Breslow thickness
4. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis
5. An analysis of prognostic factors in 8500 patients with cutaneous melanoma
6. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from John Wayne Cancer Clinic
7. Role of elective lymph node dissection in melanoma
8. Benefit of elective lymph node dissection in subgroups of melanoma patients
9. Efficacy of elective lymph node dissection in patients with intermediate-thickness primary melanoma
10. Surgical management of regional lymph nodes in patients with melanoma: Experience with 4682 patients
11. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney melanoma unit from 1960 to 1991
12. The case for elective lymphadenectomy
13. Lymphadenectomy in the management of stage 1 malignant melanoma: A prospective randomized study
14. Surgical management of malignant melanoma of the trunk and extremities
15. Malignant melanoma: Mayo Clinic experience
16. Delayed regional lymph node dissection in stage 1 melanoma of the skin of the lower extremities
17. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomized trial
18. The case against elective lymphadenectomy
19. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients
20. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: Is it standard of care?
21. Technical details of intraoperative lymphatic mapping for early-stage melanoma
22. The orderly progression of melanoma nodal metastases
23. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes
24. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma - A multicenter trial
25. Standardized probe-directed sentinel node dissection in melanoma
26. The role of sentinel lymph node mapping for melanoma
27. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma
28. A new AJCC staging system for cutaneous melanoma
29. A historical perspective on the development of intraoperative lymphatic mapping and selective lymphadenectomy
30. Elective lymph node dissection: Pros and cons
31. Role of lymphatic mapping and sentinel node biopsy in melanoma detection
32. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
33. An approach for the treatment of penile carcinoma
34. The role of sentinel lymph nodes in malignant melanoma
35. Lymphatic drainage of skin to a sentinel lymph node in a feline model
36. Gamma-probeguided lymph node localization in malignant melanoma
37. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma
38. Minimal-access surgery for staging of malignant melanoma
39. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma
40. A new radiopharmaceutical for sentinel node detection: 99mTcDTPA A-mannosyl-dextran
41. Lymphatic mapping and sentinel lymphadenectomy
42. Optimal selective sentinel lymph node dissection in primary malignant melanoma
43. Intraoperative identification of sentinel lymph node in patients with malignant melanoma
44. Reliability of sentinel lymph node biopsy for staging melanoma
45. Summary of the second international sentinel node conference
46. WHO melanoma programme: Results of sentinel node study
47. Lymphatic mapping and sentinel lymphadenectomy for melanoma
48. A redefinition of skin lymphatic drainage by lymphoscintigraphy for malignant melanoma
49. Discordancy between clinical predictions versus lymphoscintigraphic and intraoperative mapping of sentinel lymph node drainage of primary melanoma
50. Lymphoscintigraphy in high risk melanoma of the trunk: Predicting draining node groups, defining lymphatic channels and locating the sentinel node
51. Melanoma metastases through the lymphatic system
52. Introduction: Sentinel lymphadenectomy for patients with clinical stage I melanoma
53. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma
54. Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma
55. The Augsburg Consensus-Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies
56. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma
57. Detection of sub-microscopic lymph node mestastases in patients with malignant melanoma
58. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma
59. Sentinel lymph node biopsy for melanoma
60. Multi-institutional melanoma lymphatic mapping experience: Prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
61. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence
62. Outcome of patients with melanoma and histologically negative sentinel lymph nodes
63. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma
64. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Groups trial EST 1684